New Vasculitis Guidelines: How Should You Treat PAN? Staff | July 29, 2021 The ACR, in conjunction with the Vasculitis Foundation, released three new guidelines for the treatment and management of systemic vasculitis in June. Vasculitis is a group of about 20 rare diseases that have inflammation of blood vessels in common, which can restrict blood flow and damage vital organs. The three guidelines cover six forms of vasculitis, and a fourth guideline on Kawasaki disease will be released by the end of the year. The guideline for polyarteritis nodosa (PAN), a medium vessel vasculitis, provides a total of 16 recommendations and one ungraded position statement. Read the full article from The Rheumatologist, June 2021: "3 New Vasculitis Guidelines Discussed." For patients with newly diagnosed active, severe PAN, the guideline conditionally recommends initiating treatment with: A. rituximab. B. high-dose oral glucocorticoids over IV glucocorticoids. C. glucocorticoids and cyclophosphamide over glucocorticoids with rituximab. D. non-glucocorticoid immunosuppressive agents, such as azathioprine or methotrexate. None Time's up
